Management of transplant-associated thrombotic microangiopathy

• IKEZOE Takayuki

  Fukushima Medical University

Bibliographic Information

Other Title

• 造血幹細胞移植後のTMA診療
• ゾウケツ カンサイボウ イショク ゴ ノ TMA シンリョウ

Abstract

The clinical features of transplant-associated thrombotic microangiopathy (TA-TMA) include microangiopathic hemolytic anemia, consumptive thrombocytopenia, and organ dysfunction caused by thrombi in microvessels. The pathogenesis of TA-TMA is based on vascular endothelial insults caused by various factors, including chemotherapy and total-body irradiation used for transplant pre-conditioning, calcineurin inhibitors, cytokines release associated with infection, and complement factors. The incidence of TA-TMA is approximately 15-30% among allogeneic transplant patients, and the mortality rate reaches 100% in severe cases with multi-organ dysfunction. This review describes the current understanding of the pathogenesis, diagnostic criteria, and treatment strategies of this potentially lethal transplant-associated complication.

Journal

• Rinsho Ketsueki

  Rinsho Ketsueki 59 (10), 2307-2314, 2018

  The Japanese Society of Hematology

Keywords

• Transplant-associated thrombotic microangiopathy
• Endothelial insult
• thrombomodulin
• Defibrotide

Details

• CRID: 1390564238035352960
• NII Article ID: 130007496845
• NII Book ID: AN00252940
• DOI: 10.11406/rinketsu.59.2307
• ISSN: 18820824
• ISSN: 04851439
• NDL BIB ID: 029282853
• PubMed: 30305540
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I029282853
• Web Site: https://search.jamas.or.jp/link/ui/2019028277
• Text Lang: ja
• Data Source:
  • JaLC
  • NDL
  • PubMed
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed